Patents by Inventor Joseph S. Heilig

Joseph S. Heilig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Systematic evolution of ligands by exponential enrichment: tissue selex
    Patent number: 6613526
    Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: September 2, 2003
    Assignee: Gilead Sciences, Inc.
    Inventors: Joseph S. Heilig, Larry Gold
  • Systematic evolution of ligands by exponential enrichment: tissue SELEX
    Publication number: 20030027781
    Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.
    Type: Application
    Filed: February 14, 2002
    Publication date: February 6, 2003
    Inventors: Joseph S. Heilig, Larry Gold
  • Systematic evolution of ligands by exponential enrichment: tissue SELEX
    Patent number: 6376474
    Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.
    Type: Grant
    Filed: September 14, 1999
    Date of Patent: April 23, 2002
    Assignee: Gilead Sciences, Inc.
    Inventors: Joseph S. Heilig, Larry Gold
  • Systematic evolution of ligands by exponential enrichment: tissue SELEX
    Patent number: 6013443
    Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: January 11, 2000
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Joseph S. Heilig, Larry Gold